Jazz Pharma (JAZZ) Beats on Q3 Earnings, Lowers Sales View

by Zacks Equity Research Published on November 08,2018

Jazz Pharmaceuticals (JAZZ) lowers sales guidance for 2018. Stock declines 14% following the release of third-quarter earnings.

• VRTX Quick QuoteVRTXNegative Net Change
• ALKS Quick QuoteALKSNegative Net Change
• JAZZ Quick QuoteJAZZNegative Net Change
• AMRX Quick QuoteAMRXPositive Net Change

• earnings
• pharmaceuticals

Alkermes (ALKS) Exceeds Q3 Earnings Estimates, Raises Outlook

by Zacks Equity Research Published on October 23,2018

Alkermes (ALKS) surpasses earnings and sales expectations in the third quarter of 2018 and raises its financial guidance for 2018.

• MRK Quick QuoteMRKPositive Net Change
• BIIB Quick QuoteBIIBNegative Net Change
• ALKS Quick QuoteALKSNegative Net Change
• GILD Quick QuoteGILDNegative Net Change

• biotechs

Alkermes (ALKS) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research Published on October 23,2018

Alkermes (ALKS) delivered earnings and revenue surprises of 216.67% and 5.22%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

• ALKS Quick QuoteALKSNegative Net Change

• earnings
• earnings-estimates
• earnings-outlook
• earnings-surprise
• industry-outlook
• zacks-consensus-estimate
• zacks-rank

BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?

by Zacks Equity Research Published on October 22,2018

We take a look at some of the key factors of the two biotech stocks scheduled to release their third quarter results on Oct 23.

• NVS Quick QuoteNVSPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change
• RHHBY Quick QuoteRHHBYNegative Net Change
• MRK Quick QuoteMRKPositive Net Change
• BIIB Quick QuoteBIIBNegative Net Change
• ALKS Quick QuoteALKSNegative Net Change

• biotechs

Alkermes Boasts Strong Portfolio and Impressive Pipeline

by Zacks Equity Research Published on October 19,2018

Alkermes (ALKS) has a strong product portfolio, including a number of pipeline candidates with significant potential.

• MRK Quick QuoteMRKPositive Net Change
• LLY Quick QuoteLLYPositive Net Change
• ALKS Quick QuoteALKSNegative Net Change
• BIIB Quick QuoteBIIBNegative Net Change

EBS or ALKS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research Published on October 18,2018

EBS vs. ALKS: Which Stock Is the Better Value Option?

• EBS Quick QuoteEBSNegative Net Change
• ALKS Quick QuoteALKSNegative Net Change

• cloud-computing
• gold
• precious-metals
• restaurants
• retail
• value-stocks
• which-stock-is-cheaper

FDA Sets Action Date for Recro's Pain Management Candidate

by Zacks Equity Research Published on October 09,2018

The FDA has set an action date of Mar 24, 2019 for Recro's lead product candidate, intravenous (IV) meloxicam, for the management of moderate to severe pain.

• AMGN Quick QuoteAMGNNegative Net Change
• ALKS Quick QuoteALKSNegative Net Change
• CRSP Quick QuoteCRSPNegative Net Change

VistaGen Up on Fast Track Designation to Pain Candidate

by Zacks Equity Research Published on October 04,2018

VistaGen (VTGN) Fast Track designation for its pipeline candidate, AV-101, for treating neuropathic pain.

• ALKS Quick QuoteALKSNegative Net Change
• LGND Quick QuoteLGNDPositive Net Change
• VTGN Quick QuoteVTGNNo Net Change

Allergan Eyes Vraylar Label Expansion, FDA Accepts sNDA

by Zacks Equity Research Published on September 27,2018

FDA accepts Allergan's (AGN) sNDA for label expansion of its schizophrenia drug, Vraylar (cariprazine) to include treatment of bipolar depression.

• JNJ Quick QuoteJNJPositive Net Change
• AZN Quick QuoteAZNPositive Net Change
• ALKS Quick QuoteALKSNegative Net Change

Are Options Traders Betting on a Big Move in Alkermes (ALKS) Stock?

by Zacks Equity Research Published on September 19,2018

Investors need to pay close attention to Alkermes (ALKS) stock based on the movements in the options market lately.

• ALKS Quick QuoteALKSNegative Net Change

Alkermes Expands Study to Evaluate ALKS 4230-Keytruda Combo

by Zacks Equity Research Published on September 11,2018

Alkermes expands a phase I study to evaluate its immuno-oncology candidate, ALKS 4230, in combination with Keytruda in patients with advanced solid tumors.

• MRK Quick QuoteMRKPositive Net Change
• ALKS Quick QuoteALKSNegative Net Change
• LGND Quick QuoteLGNDPositive Net Change
• BIIB Quick QuoteBIIBNegative Net Change

ANIK vs. ALKS: Which Stock Is the Better Value Option?

by Zacks Equity Research Published on August 07,2018

ANIK vs. ALKS: Which Stock Is the Better Value Option?

• ANIK Quick QuoteANIKPositive Net Change
• ALKS Quick QuoteALKSNegative Net Change

What's in Store for Universal Health's (UHS) Q2 Earnings?

by Zacks Equity Research Published on July 20,2018

Universal Health's (UHS) Q2 is likely to benefit from strong performances at its Acute Care and Behavioral Health segments.

• ALKS Quick QuoteALKSNegative Net Change
• GLMD Quick QuoteGLMDPositive Net Change
• UHS Quick QuoteUHSNegative Net Change
• ALGN Quick QuoteALGNNegative Net Change

What's in the Cards for HCA Healthcare (HCA) in Q2 Earnings?

by Zacks Equity Research Published on July 20,2018

HCA Healthcare's (HCA) Q2 results are likely to be aided by a strong top line, riding on higher admissions, partially offset by increasing costs.

• ALKS Quick QuoteALKSNegative Net Change
• GLMD Quick QuoteGLMDPositive Net Change
• HCA Quick QuoteHCANegative Net Change
• ALGN Quick QuoteALGNNegative Net Change

Is a Beat in the Cards for Centene (CNC) in Q2 Earnings?

by Zacks Equity Research Published on July 19,2018

Centene's (CNC) Q2 earnings is likely to gain from higher membership and revenues from Government business.

• ALKS Quick QuoteALKSNegative Net Change
• CNC Quick QuoteCNCPositive Net Change
• ALGN Quick QuoteALGNNegative Net Change

Alkermes' Aristada Initio Approved by FDA for Schizophrenia

by Zacks Equity Research Published on July 03,2018

FDA approves Alkermes' (ALKS) Aristada Initio (aripiprazole lauroxil) for the treatment of schizophrenia in adults.

• ILMN Quick QuoteILMNNegative Net Change
• ALKS Quick QuoteALKSNegative Net Change
• ANIP Quick QuoteANIPNegative Net Change

Company News For Jul 3, 2018

by Zacks Equity Research Published on July 03,2018

Companies in the news are: CLB, ALKS, ACXM and URI

• URI Quick QuoteURINegative Net Change
• ALKS Quick QuoteALKSNegative Net Change
• CLB Quick QuoteCLBPositive Net Change

Key FDA Events in June Investors Need to Watch Out For

by Zacks Equity Research Published on June 01,2018

Investors in the healthcare industry are likely to keep a watch on upcoming PDUFA dates for key drugs in Jun 2018.

• MRK Quick QuoteMRKPositive Net Change
• ALKS Quick QuoteALKSNegative Net Change
• ARRY Quick QuoteARRYNegative Net Change

The Zacks Analyst Blog Highlights: Seagate, Grafton, Ingersoll-Rand and Alkermes

by Zacks Equity Research Published on May 11,2018

The Zacks Analyst Blog Highlights: Seagate, Grafton, Ingersoll-Rand and Alkermes

• STX Quick QuoteSTXNegative Net Change
• IR Quick QuoteIRPositive Net Change
• ALKS Quick QuoteALKSNegative Net Change
• GROUF Quick QuoteGROUFNegative Net Change

4 Top Stocks to Buy As Irish Economy Gathers Steam

by Nitish Marwah Published on May 10,2018

EU remains upbeat about growth prospects of the Irish economy in the years to come.

• STX Quick QuoteSTXNegative Net Change
• IR Quick QuoteIRPositive Net Change
• ALKS Quick QuoteALKSNegative Net Change
• GROUF Quick QuoteGROUFNegative Net Change

Alkermes (ALKS) Reports Wider-Than-Expected Loss in Q1

by Zacks Equity Research Published on April 27,2018

Alkermes (ALKS) posts wider than expected loss in the first quarter of 2018. However, sales beat estimates.

• ALKS Quick QuoteALKSNegative Net Change
• BIIB Quick QuoteBIIBNegative Net Change
• LGND Quick QuoteLGNDPositive Net Change
• PTGX Quick QuotePTGXPositive Net Change

BioMarin (BMRN) Q1 Earnings Lower Than Expected, Sales Beat

by Zacks Equity Research Published on April 26,2018

BioMarin (BMRN) reported mixed first-quarter results with earnings missing estimates but sales beating the same.

• SNY Quick QuoteSNYPositive Net Change
• BMRN Quick QuoteBMRNNegative Net Change
• ALKS Quick QuoteALKSNegative Net Change
• LGND Quick QuoteLGNDPositive Net Change

Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics

by Zacks Equity Research Published on April 18,2018

The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.

• ALKS Quick QuoteALKSNegative Net Change
• GILD Quick QuoteGILDNegative Net Change
• CLDX Quick QuoteCLDXNegative Net Change

Alkermes Rallies as FDA Accepts NDA for Depression Drug

by Zacks Equity Research Published on April 17,2018

Shares of Alkermes (ALKS) rose when the FDA accepted for review the new drug application for its depression candidate ALKS 5461 two weeks after it had issued a Refusal to File letter.

• ALKS Quick QuoteALKSNegative Net Change
• LGND Quick QuoteLGNDPositive Net Change
• PTGX Quick QuotePTGXPositive Net Change

Company News For Apr 17, 2018

by Zacks Equity Research Published on April 17,2018

Companies In The News are: JBHT,ERI,MRK,ALKS

• JBHT Quick QuoteJBHTNegative Net Change
• MRK Quick QuoteMRKPositive Net Change
• ALKS Quick QuoteALKSNegative Net Change